Avalo Therapeutics, INC Form 4 insider transactions
NASDAQ
Form 4: Avalo Therapeutics CFO Christopher Ryan Sullivan Awarded Stock Options and Restricted Stock Units
Christopher Ryan Sullivan, CFO of Avalo Therapeutics, Inc., received stock options and restricted stock units on August 13, 2024.
NASDAQ
Avalo Therapeutics CEO Garry Arthur Neil was granted stock options and restricted stock units on August 13, 2024, according to a Form 4 filing.
NASDAQ
A Form 4 filing reveals that Avalo Therapeutics' Chief Medical Officer, Mittie Doyle, was granted stock options on July 15, 2024.
NASDAQ
Paul Varki, Chief Legal Officer of Avalo Therapeutics, reports the acquisition of stock options.